Results 201 to 210 of about 819,536 (350)
A Rubik's Cube-Inspired Pedagogical Tool for Teaching and Learning Engineering Ethics. [PDF]
Peng Y.
europepmc +1 more source
Commentary on Learning and Educational Objectives of Engineering Ethics Education
小林 幸人, 札野 順
openalex +2 more sources
ABSTRACT Mutations in myelin regulatory factor (MYRF) are linked to demyelinating disorders. We report a 38‐year‐old male who developed acute symmetric leukoencephalopathy mimicking a stroke following an influenza A virus infection. While clinical symptoms markedly improved with corticosteroids, MRI revealed persistent white matter lesions, contrasting
Jinghan Hu +5 more
wiley +1 more source
Empathy's Role in Engineering Ethics: Empathizing with One's Self to Others Across the Globe. [PDF]
Hess JL.
europepmc +1 more source
ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai +28 more
wiley +1 more source
The Role of Engineering Ethics in Mitigating Corruption in Infrastructure Systems Delivery. [PDF]
Ghahari SA, Queiroz C, Labi S, McNeil S.
europepmc +1 more source
ABSTRACT Pathogenic variants in KIF1C cause Spastic Paraplegia 58 (SPG58), typically presenting with cerebellar ataxia and spastic paraparesis. We report two unrelated patients with spastic paraparesis, cerebellar ataxia, and tremor. Whole‐exome sequence analysis identified novel homozygous variants in the motor domain of KIF1C (NM_006612.6): c.921G>A (
Akihiko Mitsutake +12 more
wiley +1 more source
Australia II: A Case Study in Engineering Ethics. [PDF]
van Oossanen P, Peterson M.
europepmc +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source

